The Journal of Internal Korean Medicine (대한한방내과학회지)

The Society of Internal Korean Medicine (대한한방내과학회)
권호 표지
DOI QR코드

DOI QR Code

Case Report on the Five-year Survival and Complete Response of a Patient with Pancreatic Cancer Treated with Integrative Medicine

통합 의학 치료로 5년 생존 및 완전 관해에 도달한 췌장암 증례 보고 1례

  • Received : 2023.05.31
  • Accepted : 2023.07.06
  • Published : 2023.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives: This is a five-year survival and complete response (CR) report on pancreatic cancer treated with western medicine and Korean traditional medicine. Method: A 59-year-old woman diagnosed with pancreatic cancer visited ○○ Korean traditional medicine hospital after neoadjuvant chemotherapy and pylorus-preserving pancreaticoduodenectomy. She was treated with Korean traditional medicine, including acupuncture, abdominal moxibustion, wild ginseng pharmacopuncture, and herbal medicine, which was based on integrated medicine therapy (IMT), from March 2018 to September 2022. The tumor size was measured by scanning with computed tomography (CT), magnetic resonance imaging, and positron-emission tomography/CT. Adverse events were evaluated using laboratory conclusion and National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. Result: During four years and three months of treatment, IMT maintained safety. The patient finally reached five-year survival without any recurrence or complication (CR) on October 26, 2022. Conclusion: We suggest that an integrative approach including Korean traditional medicine can be a meaningful treatment option for pancreatic cancer. Further studies should be performed to establish the proper treatment protocol of integrative medicine for pancreatic cancer.

Keywords

References

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62(1):10-29.  https://doi.org/10.3322/caac.20138
  2. Siegel R, Miller K, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70(1):7-30.  https://doi.org/10.3322/caac.21590
  3. National Comprehensive Cancer Network [internet]. Plymouth Meeting, USA: National Comprehensive Cancer Network;[cited 2019 Jan 20]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf. 
  4. Bang SM. Surveillance and early diagnosis of pancreatic cancer. The Korean Journal of Pancreas and Biliary Tract 2015;20(1):1-4.  https://doi.org/10.15279/kpba.2015.20.1.1
  5. Kim JW. Recent treatment of pancreatic cancer. Korean J Med 2009;77(6):695-702. 
  6. Ryu JK. Recent Advances in Palliative Chemotherapy for Unresectable Pancreatic Cancer. Korean J Gastroenterol 2015;66(3):150-3.  https://doi.org/10.4166/kjg.2015.66.3.150
  7. Park JG, Bang YJ, Ha SH. Oncology. Seoul: Iljogak; 2012, p. 317-8, 327-9, 330-1. 
  8. Han GJ, Jeong HY, Park EJ, Lee AR, Lee JM, Seong S, et al. Review of Domestic Research on Korean Medicine for Pancreatic Cancer. J Int Korean Med 2019;40(1):70-88.  https://doi.org/10.22246/jikm.2019.40.1.70
  9. Schmitz H, Courneya KS, Matthews C, Demark -Wahnefried W, Galvao DA, Pinto BM, et al. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc 2010;42(7):1409-26.  https://doi.org/10.1249/MSS.0b013e3181e0c112
  10. Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy isassociated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 2001;19(14):3306-10.  https://doi.org/10.1200/JCO.2001.19.14.3306
  11. Li M, Wang MM, Guo XW, Wu CY, Li DR, Zhang X, et al. Different Survival Benefits of Chinese Medicine for Pancreatic Cancer: How to Choose? Chin J Integr Med 2018;24(3):178-84.  https://doi.org/10.1007/s11655-017-2971-1
  12. Ko EJ, Myong JS, Kim JH, Park JH, Park SJ, Lee YW, et al. A Case Report of Pancreatic Cancer with Liver Metastasis Patient Treated with Integrative Cancer Treatment. J of Kor Traditional Oncology 2021;26(1):39-48. 
  13. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R. New response evaluation criteria in solid tumours: Revised RECIST guideline(version1.1). Eur J Cancer 2009;45(2):228-47.  https://doi.org/10.1016/j.ejca.2008.10.026
  14. Ko EB, Jang KJ, Jang JY, Song MH, Shin KS. A Case Report of Partial Remission of End-stage Pancreatic Cancer Patient with Liver Metastasis Treated with Chemotherapy and Integrated Medicine Therapy. J Int Korean Med 2020;41(2):166-76.  https://doi.org/10.22246/jikm.2020.41.2.166
  15. Sharma S. Tumor markers in clinical practice: General principle sand guidelines. Indian journal of medical and paediatric oncology. official journal of Indian Society of Medical & Paediatric Oncology 2009;30(1):1-8. 
  16. Korean Central Cancer Registry. Annual report of Korean Central Cancer Registry (2017). 2020. 
  17. Lee KS, Chang HS, Lee SM, Park EC. Economic burden of cancer in Korea during 2000-2010. Cancer Res Treat 2015;47(3):387-98.  https://doi.org/10.4143/crt.2014.001
  18. Isaji S, Mizuno S, Windsor JA, Bassi C, Fernandez-Del Castillo C, Hackert T, et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology 2018;18(1):2-11.  https://doi.org/10.1016/j.pan.2017.11.011
  19. National Comprehensive Cancer Network, pancreatic adenocarcinoma, version 1. 2020, NCCN clinical practice guidelines in oncology. 
  20. Korean Clinical Practice Guideline Development Committee. Korean clinical practice guideline for pancreatic cancer 2021: A summary of evidence-based, multi-disciplinary diagnostic and therapeutic approaches. 2021, p. 10, 58-61, 77-91. 
  21. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15(6):2403-13.  https://doi.org/10.1200/JCO.1997.15.6.2403
  22. Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet 2020;395(10242):2008-20.  https://doi.org/10.1016/S0140-6736(20)30974-0
  23. Leonhardt CS, Traub B, Hackert T, Klaiber U, Strobel O, Buchler MW, et al. Adjuvant and neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma. J Pancreatol 2020;3:1-11.  https://doi.org/10.1097/JP9.0000000000000040
  24. Catenacci DV, Junttila MR, Karrison T, Bahary N, Horiba MN, Nattam SR, et al. Randomized phase Ib/II study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer. J Clin Oncol 2015;33(36):4284-92.  https://doi.org/10.1200/JCO.2015.62.8719
  25. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364(19):1817-25.  https://doi.org/10.1056/NEJMoa1011923
  26. Kim JM, Park JW, Yoo HS, Lee YW, Cho CK. Case Report of the Pancreatic Cancer Patient after Pancreatoduodenectomy who is Taking the HangAm-Plus to Anti-metastasis and Preventing Recurrence. J of Kor Traditional Oncology 2011;16(1):33-9. 
  27. Joo HE, Park JH, Song SY, Cho YM, Park SJ, Yoo HS. A Case Report of Traditional Korean Medicine Based-Integrative Oncology of Recurrent Pancreatic Cancer. J of Kor Traditional Oncology 2022;27(1);1-12. 
  28. Troger W, Galun D, Reif M, Schumann A, Stankovic N, Milicevic M. Viscum album[L.] extract therapy in patients with locally advanced or metastatic pancreatic cancer: A randomised clinical trial on overall survival. European Journal of Cancer 2013;49(18):3788-97.  https://doi.org/10.1016/j.ejca.2013.06.043
  29. Rasi G, Silecchia G, Sinibaldi-Vallebona P. Anti-tumor effect of combined treatment with thymosin alpha 1 and interleukin-2 after 5-fluorouracil in liver metastases from colorectal cancer in rats. International Jounal of Cancer 1994;57(5):701-5.  https://doi.org/10.1002/ijc.2910570516
  30. Townsend DM, Tew KD. The role of glutathione -S-transferase in anti-cancer drug resistance. Oncogene 2003 Oct 20;22(47):7369-75.  https://doi.org/10.1038/sj.onc.1206940
  31. Fritz H, Flower G, Weeks L, Cooley K, Callachan M, McGowan J, et al. Intravenous Vitamin C and Cancer: A Systematic Review. Integr Cancer Ther 2014 May;13(4):280-300.  https://doi.org/10.1177/1534735414534463
  32. Yuhan X, Shuaibing W, Beibei Y, Su L, Yiyi D, Hong L. Adjuvant treatment for triple-negative breast cancer: a retrospective study of immunotheraphy with autologous cytokine-induced killer cells in 294 patients. Cancer Biol Med 2019 May;16(2):350-60.  https://doi.org/10.20892/j.issn.2095-3941.2018.0378
  33. Park SJ, Yoo HS, Yu JS. Preliminary Study for Development of Korean Medicine Clinical Practice Guideline for Pancreatic Cancer. J of Kor Traditional Oncology 2017;22(1):1-11. 
  34. Oh SM, Cheon CH, Park SJ, Jang BH, Park JS, Jang SB, et al. The Analysis of the Recent Research Trend of Sipjeondabo-tang in Korea. Journal of Society of Preventive Korean Medicine 2014;18(1):113-23. 
  35. Lee SY, Kim JH. Effects of Samculkunbitang of the Immunosuppression Induced by Methrotrexate in Rats. The Journal of Pediatrics of Korean Medicine 1998;12(1):257-76. 
  36. Joo EJ, Chun J, Ha YW, Ko HJ, Xu MY, Kim YS. Novel roles of ginsenoside Rg3 in apoptosis through downregulation of epidermal growth factor receptor. Chem Biol Interact 2015;233:25-34.  https://doi.org/10.1016/j.cbi.2015.03.016
  37. Elluru S, Duong Van Huyen JP, Delignat S, Prost F, Bayry J, Kazatchkine MD, et al. Molecular mechanisms underlying the immunomodulatory effects of mistletoe (Viscum album L.) extracts Iscador. Arzneimittelforschung 2006;56(6):461-6.